Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Association Areas of the Cortex

Association Areas of the Cortex

Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case management by Norwegian municipal dementia resource teams - fulfilling the role.

Aging & mental health·2026

Same author

Potentially inappropriate medications related to two-year progression of mild cognitive impairment and dementia.

European journal of clinical pharmacology·2026

Same author

Automatic MRI Volumetry Assisted Visual Assessment of the Medial Temporal Lobe in Clinical Dementia Work-Up.

Brain and behavior·2025

Same author

Psychometric evaluation of the Norwegian version of the Threadgold Communication Tool.

International journal of nursing studies advances·2025

Same author

Incidence of dementia among individuals 70 years and older in Norway: A HUNT study.

Journal of Alzheimer's disease : JAD·2025

Same author

Personalised Prevention of Falls in Persons with Dementia-A Registry-Based Study.

Geriatrics (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Frontotemporal dementia: a clinically complex diagnosis.

Tor Atle Rosness¹, Per Kristian Haugen, Ulla Passant

¹Norwegian Centre for Dementia Research, Department of Geriatric Medicine, Ullevaal University Hospital, Oslo, Norway. tor.rosness@aldringoghelse.no <tor.rosness@aldringoghelse.no>

International Journal of Geriatric Psychiatry

|February 28, 2008

Summary

Diagnosing Frontotemporal dementia (FTD) takes significantly longer than early onset Alzheimer's dementia (AD). Increased awareness of FTD symptoms in healthcare settings is crucial for timely diagnosis.

Related Experiment Videos

Last Updated: Jul 7, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Area of Science:

Neurology
Geriatrics
Cognitive Science

Background:

Frontotemporal dementia (FTD) and early onset Alzheimer's dementia (AD) are distinct neurodegenerative conditions.
Diagnostic delays for FTD can impact patient management and outcomes.

Purpose of the Study:

To compare the diagnostic timelines for FTD versus early onset AD.
To identify factors contributing to diagnostic delays in FTD.

Main Methods:

Retrospective analysis of 89 patients under 65 years old.
Inclusion of patients meeting Manchester-Lund criteria for FTD and ICD-10 criteria for early onset AD.
Data collected from Norway and Sweden.

Main Results:

FTD diagnosis took longer than AD diagnosis, both from illness onset (59.2 months vs. 39.1 months) and first medical visit (34.5 months vs. 25.9 months).
A significant proportion of FTD patients (71%) and AD patients (30%) initially received an incorrect non-dementia diagnosis.
Diagnostic delays varied between Norway and Sweden for FTD patients.

Conclusions:

There is a need for enhanced knowledge of early FTD signs in primary and secondary care.
Improving diagnostic accuracy and reducing delays for FTD is essential.
Further research into early FTD detection is warranted.